Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of MRG-201 Following Intradermal Injection in Subjects With a History of Keloids

Next Previous
Search
Trial Profile

A Phase 2, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of MRG-201 Following Intradermal Injection in Subjects With a History of Keloids

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remlarsen (Primary)
  • Indications Fibrosis; Keloids
  • Focus Therapeutic Use
  • Sponsors miRagen Therapeutics; Viridian Therapeutics

Most Recent Events

  • 18 Nov 2020 Status changed from active, no longer recruiting to completed.
  • 07 May 2020 According to a miRagen Therapeutics media release, the company is currently working to complete its analysis of the one-year primary endpoint data of this trial. Due to the COVID-19 pandemic on clinical sites, the Company cannot accurately predict when it will report the final topline data from this clinical trial, which was previously expected to be released in the second half of 2020.
  • 11 Dec 2019 According to a miRagen Therapeutics media release, based on the interim data the Company has decided to continue its analysis of patient data at the one-year primary endpoint of the clinical trial. With this data, the Company may seek a collaboration partner for the future development of remlarsen.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top